Dataset Information
Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition.
Ontology highlight
ABSTRACT: Objective
To study the effect of exenatide on body composition and circulating cardiovascular risk biomarkers.Research design and methods
Metformin-treated patients with type 2 diabetes (N = 69) were randomized to exenatide or insulin glargine and treated for 1 year. Body composition was evaluated by dual-energy X-ray absorptiometry. Additionally, body weight, waist circumference, and cardiovascular biomarkers were measured.Results
Treatment with exenatide for 1 year significantly reduced body weight, waist circumference, and total body and trunkal fat mass by 6, 5, 11, and 13%, respectively. In addition, exenatide increased total adiponectin by 12% and reduced high-sensitivity C-reactive protein by 61%. Insulin glargine significantly reduced endothelin-1 by 7%. These changes were statistically independent of the change in total body fat mass and body weight.Conclusions
Exenatide treatment for 1 year reduced body fat mass and improved the profile of circulating biomarkers of cardiovascular risk. No significant changes were seen with insulin glargine except a trend for reduced endothelin-1 levels.
SUBMITTER: Bunck MC
PROVIDER: S-EPMC2909051 | biostudies-literature | 2010 Aug
REPOSITORIES: biostudies-literature
Publications
Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition.
Diabetes care 20100427 8
<h4>Objective</h4>To study the effect of exenatide on body composition and circulating cardiovascular risk biomarkers.<h4>Research design and methods</h4>Metformin-treated patients with type 2 diabetes (N = 69) were randomized to exenatide or insulin glargine and treated for 1 year. Body composition was evaluated by dual-energy X-ray absorptiometry. Additionally, body weight, waist circumference, and cardiovascular biomarkers were measured.<h4>Results</h4>Treatment with exenatide for 1 year sign ...[more]